useddedge
11-06-2022, 01:10 AM
Patients with advanced HER2 negative metastatic breast cancer and high tumor mutational burden achieved responses often durable from treatment with the immunotherapy doublet of nivolumab and ipilimumab, according to the results of the phase II NIMBUS trial reported at the 2021 San Antonio Breast stromectol spc ([Only registered and activated users can see links])